Latest Information Update: 28 Aug 2007
At a glance
- Originator DOR BioPharma
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Trypanosomiasis; Viral infections
Most Recent Events
- 05 Jan 2000 No-Development-Reported for Trypanosomiasis in USA (Unknown route)
- 05 Jan 2000 No-Development-Reported for Viral infections in USA (Unknown route)
- 27 Mar 1997 New profile